Differential modulation of the androgen receptor for prostate cancer therapy depends on the DNA response element

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Androgen receptor (AR) signaling is crucial in prostate cancer (PCa) pathogenesis.
• Therapeutic resistance and aberrant AR signaling drive PCa progression.
• Identifying compounds that selectively inhibit cancer-driving genes is a therapeutic goal.

Purpose of the Study:

• To discover compounds that inhibit genes driving PCa but not normal growth.
• To investigate the differential effects of doxorubicin (dox) on AR target genes.
• To explore the potential repurposing of doxorubicin for PCa treatment.

Main Methods:

• High-throughput promoter-dependent drug screening.
• Transcriptomic analysis (RNA-seq) to assess gene expression changes.
• Chromatin immunoprecipitation (ChIP) and ChIP-sequencing (ChIP-seq) to evaluate AR binding dynamics.

Main Results:

• Low-dose doxorubicin selectively downregulated cell cycle genes in PCa cells.
• Doxorubicin altered AR binding patterns, increasing binding at selective androgen response elements (sAREs) and decreasing it at consensus AREs (cAREs).
• Doxorubicin's effects were observed in multiple PCa cell lines and in vivo.

Conclusions:

• Doxorubicin exhibits differential modulation of AR signaling at low doses, potentially by interacting with cofactors at sAREs.
• This selective inhibition of cancer-promoting genes offers a novel therapeutic strategy for PCa.
• Repurposing doxorubicin may provide unique opportunities for treating advanced prostate cancer.